Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Clemens

Showing results (321-330 of 395) with videos related to

Pageof 40
Sort By:
Muscle & Nerve|June 16, 2011
Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophyAngela Zimmerman, Paula R Clemens, Carolina Tesi-Rocha, et al.
Human Immunology|May 6, 1998
The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAgT Höhler, C U Meyer, A Notghi, et al.
Muscle & Nerve|December 6, 2013
Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophyMolly F Wood, Sarah C Hughes, Lauren P Hache, et al.
Journal of Neuromuscular Diseases|April 3, 2023
Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension StudyPaula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Journal of Neuromuscular Diseases|May 31, 2022
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver diseaseE B Keeffe, S Iwarson, B J McMahon, et al.
Neurology|September 1, 2017
High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2James E Hilbert, Richard J Barohn, Paula R Clemens, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 7, 2011
Current status of pharmaceutical and genetic therapeutic approaches to treat DMDChristophe Pichavant, Annemieke Aartsma-Rus, Paula R Clemens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancyM Pecherstorfer, Z Herrmann, J J Body, et al.
Journal of Molecular Biology|October 4, 2005
Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinantsSusan J Gagnon, Oleg Y Borbulevych, Rebecca L Davis-Harrison, et al.
Pageof 40

Showing results (321-330 of 395) with videos related to

Sort By:
Pageof 40
Muscle & Nerve|June 16, 2011
Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophyAngela Zimmerman, Paula R Clemens, Carolina Tesi-Rocha, et al.
Human Immunology|May 6, 1998
The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAgT Höhler, C U Meyer, A Notghi, et al.
Muscle & Nerve|December 6, 2013
Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophyMolly F Wood, Sarah C Hughes, Lauren P Hache, et al.
Journal of Neuromuscular Diseases|April 3, 2023
Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension StudyPaula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Journal of Neuromuscular Diseases|May 31, 2022
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver diseaseE B Keeffe, S Iwarson, B J McMahon, et al.
Neurology|September 1, 2017
High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2James E Hilbert, Richard J Barohn, Paula R Clemens, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 7, 2011
Current status of pharmaceutical and genetic therapeutic approaches to treat DMDChristophe Pichavant, Annemieke Aartsma-Rus, Paula R Clemens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancyM Pecherstorfer, Z Herrmann, J J Body, et al.
Journal of Molecular Biology|October 4, 2005
Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinantsSusan J Gagnon, Oleg Y Borbulevych, Rebecca L Davis-Harrison, et al.
Pageof 40